(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 August 2009 (13.08.2009)

PCT

(10) International Publication Number
WO 2009/099594 A1

(51) **International Patent Classification**:
A61K 31/535 (2006.01)

(21) **International Application Number**:
PCT/US2009/000686

(22) **International Filing Date**:
2 February 2009 (02.02.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/026,067 4 February 2008 (04.02.2008) US

(71) **Applicant** *(for all designated States except US)*: **CYTOKINETICS, INCORPORATED** [US/US]; 280 East Grand Avenue, South San Francisco, California 94080 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **YANG, Zhe** [US/US]; 1621 Graystone Ln., Daly City, California 94014 (US). **COLLIBEE, Scott** [US/US]; 2065 Brittan Avenue, San Carlos, California 94070 (US). **MUCI, Alex** [US/US]; 2025 Stockton Street, #3, San Francisco, California 94133 (US). **WANG, Jianchao** [CA/US]; 489 Nantucket Street, Foster City, California 94404 (US). **GARDINA, Jeff** [US/US]; 280 East Grand Avenue, South San Francisco, California 94080 (US). **ASHCRAFT, Luke W.** [US/US]; 668 Carolina St., San Francisco, California 94107 (US). **STOLTZ, Brian** [US/US]; 1954 East California Blvd., San Marino, California 91108 (US). **BERGNES, Gustave** [US/US]; 74 Kathleen Court, Pacifica, California 94044 (US). **MORGAN, Bradley P.** [US/US]; 1206 Rimer Drive, Moraga, California 94556 (US).

(74) **Agent**: **STEVENS, Lauren L.**; Finnegan, Henderson, Farabow, Garrett & Dunner LLP, 901 New York Avenue, N.W., Washington, D.c., District Of Columbia 20001-4413 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2009/099594 A1

(54) **Title**: CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

(57) **Abstract**: Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of neuromuscular disorders, conditions having muscle wasting, claudication, frailty, metabolic syndrome, muscle atrophy associated with disuse, and muscle fatigue, and other indications.